Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
VEGF-A inhibitor
DRUG CLASS:
VEGF-A inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
bevacizumab (354)
bevacizumab-maly (12)
Aybintio (bevacizumab biosimilar) (12)
bevacizumab-awwb (11)
bevacizumab-adcd (11)
bevacizumab-bvzr (8)
aflibercept intravitreal (7)
Krabeva (bevacizumab biosimilar) (7)
Byvasda (bevacizumab biosimilar) (4)
ziv-aflibercept IV (4)
bevacizumab (354)
bevacizumab-maly (12)
Aybintio (bevacizumab biosimilar) (12)
bevacizumab-awwb (11)
bevacizumab-adcd (11)
bevacizumab-bvzr (8)
aflibercept intravitreal (7)
Krabeva (bevacizumab biosimilar) (7)
Byvasda (bevacizumab biosimilar) (4)
ziv-aflibercept IV (4)
›
Associations
(430)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
Businesswire - 2 weeks (New B)
bevacizumab + atezolizumab
Sensitive
:
A1
Businesswire - 2wk
bevacizumab + atezolizumab
Sensitive: A1 - Approval
Businesswire - 2 weeks
bevacizumab + atezolizumab
Sensitive
:
A1
Businesswire - 2 weeks - (New B)
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
bevacizumab
Sensitive
:
C2
ASCO-GI 2023 - 2wk
bevacizumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
bevacizumab
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HRD
Ovarian Cancer
HRD
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks (New B)
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3wk
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3 weeks - (New B)
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks (New B)
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3wk
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3 weeks - (New B)
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks (New B)
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3wk
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3 weeks - (New B)
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Fallopian Tube Cancer
HRD
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Peritoneal Cancer
HRD
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
bevacizumab + atezolizumab
Sensitive
:
A1
bevacizumab + atezolizumab
Sensitive: A1 - Approval
bevacizumab + atezolizumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Cervical Cancer
No biomarker
Cervical Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Cervical Cancer
No biomarker
Cervical Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
bevacizumab + atezolizumab
Sensitive
:
A1
bevacizumab + atezolizumab
Sensitive: A1 - Approval
bevacizumab + atezolizumab
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Cervical Cancer
No biomarker
Cervical Cancer
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab-bvzr
Resistant: A1 - Approval
bevacizumab-bvzr
Resistant
:
A1
bevacizumab-bvzr
Resistant: A1 - Approval
bevacizumab-bvzr
Resistant
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login